Zhang Yi, Li Xuelin, Zhang Xiaobei, Wang Tiantian, Zhang Xiangcheng
Department of Critical Care Medicine, The Affiliated Huai'an No 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.
Front Med (Lausanne). 2024 Jul 3;11:1398024. doi: 10.3389/fmed.2024.1398024. eCollection 2024.
Sepsis is a intricate pathological process characterized by life-threatening organ dysfunction resulting from a dysregulated host response to infection. It stands as a prominent cause of mortality among critically ill patients globally. The pivotal focus in sepsis management lies in the early identification and prompt administration of antimicrobial agents. Owing to the constraints of current diagnostic methodologies, marked by insufficient sensitivity and delayed outcomes, extensive research has been undertaken to ascertain novel biomarkers for sepsis. In this review, we provide an overview discussing the latest advancements in the study of PTX-3 as a biomarker for sepsis. We acknowledge pivotal discoveries from preceding research and engage in discourse regarding the challenges and limitations confronted by PTX-3 as a sepsis biomarker.
脓毒症是一种复杂的病理过程,其特征是宿主对感染的反应失调导致危及生命的器官功能障碍。它是全球危重症患者死亡的主要原因。脓毒症管理的关键在于早期识别和及时使用抗菌药物。由于目前诊断方法存在灵敏度不足和结果延迟的局限性,人们进行了广泛研究以确定脓毒症的新型生物标志物。在本综述中,我们概述了作为脓毒症生物标志物的PTX-3研究的最新进展。我们认可先前研究的关键发现,并讨论PTX-3作为脓毒症生物标志物所面临的挑战和局限性。